- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 1 Feb 24 EFFECT Notice of effectiveness
- 26 Jan 24 POS AM Prospectus update (post-effective amendment)
- 18 Aug 22 424B3 Prospectus supplement
- 4 Aug 22 424B4 Prospectus supplement with pricing info
- 4 Aug 22 EFFECT Notice of effectiveness
-
2 Aug 22 S-1/A IPO registration (amended)
- 22 Jul 22 FWP Free writing prospectus
- 20 Jul 22 S-1/A IPO registration (amended)
- 1 Jul 22 S-1/A IPO registration (amended)
- 11 Feb 22 S-1 IPO registration
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the incorporation by reference in this Registration Statement of Navidea Biopharmaceuticals, Inc. on Amendment # 3 to the Form S-1 (Registration No. 333-262691) of our report dated March 28, 2022, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Navidea Biopharmaceuticals, Inc. as of December 31, 2021 and 2020 and for the years ended December 31, 2021 and 2020 appearing in the Annual Report on Form 10-K of Navidea Biopharmaceuticals, Inc. for the year ended December 31, 2021. We also consent to the reference to our firm under the heading “Experts” in the Prospectus, which is part of this Registration Statement.
/s/ Marcum LLP
Marcum LLP
Hartford, CT
August 2, 2022